Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1010-1015

  Yeh, Jason ^a   Frieze, Deborah ^a   Martins, Renato ^a   Carr, Laurie ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Proteinuria; Recombinant humanized monoclonal antibody; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB;

ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; HEALTH CARE COST; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METASTASIS; PRIORITY JOURNAL; PROTEINURIA; SOLID TUMOR; TREATMENT PLANNING; VIRUS HEPATITIS;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; FEMALE; HUMANS; PROTEINURIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952920167     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M670     Document Type: Article

References (24)

1. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009;66:999-1013. DOI 10.2146/ajhp080455
2. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-1802 DOI 10.1016/j.clinthera.2006.11.015 (Pubitemid 46038527)
3. Van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-2995 DOI 10.1200/JCO.2007.11.5113 (Pubitemid 47218042)
4. Eremina V, Jefferson J, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136 DOI 10.1056/NEJMoa0707330
5. Product information. Avastin (bevacizumab). San Francisco, CA: Genentech, Inc., March 2009.
6. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon-alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007;370:2103-2111 DOI 10.1016/S0140-6736(07)61904-7
7. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-2998 DOI 10.1200/JCO.2007.15.9947
8. Ning YM, Arlen PM, Gulley J, et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC) (abstract 5000). J Clin Oncol 2008;26:250s.
9. Vervenne W, Bennouna J, Humblet Y, et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (abstract 4507). J Clin Oncol 2008;26:214S.
10. George B, Zhou X, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007;49:e23-9. DOI 10.1053/j.ajkd.2006.11.024
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 DOI 10.1056/NEJMoa032691
12. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550 DOI 10.1056/NEJMoa061884
13. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666-2676 DOI 10.1056/NEJMoa072113
14. Zhu X, Wu S, Dahut W, Parikh C. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49: 186-193 DOI 10.1053/j.ajkd.2006.11.039
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. www.kidney.org/professionals/kdoqi/guidelines-ckd/toc.htm (accessed 2009 Jul 28).
16. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ 2008;336: 1185-1189 DOI 10.1136/bmj.39576.709711.80
17. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009;43:490-501. DOI 10.1345/aph.1L426.
18. Martel C, Presant C, Ebrahami B, et al. Bevacizumab-related toxicities: association of hypertension and proteinuria. http://www.communityoncology. net/journal/articles/0302090.pdf (accessed 2009 Mar 10).
19. Martel CL, Ebrahimi B, Horns RC, et al. Incidence of bevacizumab (BE) related toxicities: association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS) (abstract 8062). J Clin Oncol 2005;23(suppl):16S.
20. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434 DOI 10.1056/NEJMoa021491
21. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903 DOI 10.1200/JCO.2005.04.9130
22. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int 2005;67:285-290 DOI 10.1111/j.1523-1755.2005.00080.x
23. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17:1168-1174 DOI 10.1681/ASN.2005091006
24. Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis 2008;51:885-892 DOI 10.1053/j.ajkd.2008.03.009